MCID: GLC036
MIFTS: 46

Glucagonoma malady

Categories: Rare diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Glucagonoma

Aliases & Descriptions for Glucagonoma:

Name: Glucagonoma 50 56 52 69
Glucagonoma Syndrome 50 56 29
Weight Loss, Necrolytic Migratory Erythema , Diabetes, Stomatitis, and Diarrhea 50

Characteristics:

Orphanet epidemiological data:

56
glucagonoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Orphanet 56 ORPHA97280
MESH via Orphanet 43 D005935
UMLS via Orphanet 70 C0017689
ICD10 via Orphanet 34 E16.8

Summaries for Glucagonoma

MalaCards based summary : Glucagonoma, also known as glucagonoma syndrome, is related to short bowel syndrome and pheochromocytoma, and has symptoms including pruritus, constipation and diarrhea. An important gene associated with Glucagonoma is SST (Somatostatin), and among its related pathways/superpathways are G alpha (s) signalling events and Gastric acid production. The drugs pancreatic polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include pancreas, skin and liver.

Wikipedia : 71 A glucagonoma is a rare tumor of the alpha cells of the pancreas that results in the overproduction of... more...

Related Diseases for Glucagonoma

Diseases related to Glucagonoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
id Related Disease Score Top Affiliating Genes
1 short bowel syndrome 29.5 SCT SST
2 pheochromocytoma 28.8 CHGA CHGB SST VIP
3 appendiceal l-cell glucagon-like peptide producing tumor 10.8
4 pancreatitis 10.3
5 secondary syphilis 10.2 CHGA SST
6 brain edema 10.2 CHGA SST
7 oculocutaneous albinism 10.2 CHGA SST
8 breast secretory carcinoma 10.2 CHGA SST
9 adult botryoid rhabdomyosarcoma 10.2 CHGA SST
10 cowden syndrome 3 10.2 CHGA SST
11 non-syndromic x-linked intellectual disability 10.2 CHGA SST
12 tricuspid valve stenosis 10.2 SCT SST
13 tooth erosion 10.2 SCT SST
14 peripheral degeneration of cornea 10.2 SCT SST
15 protein s deficiency 10.2 GHRH SST
16 tabes dorsalis 10.1 SCT SST
17 immune system organ benign neoplasm 10.1 GHRH SST
18 meige syndrome 10.1 CHGA SST
19 neurogenic arthropathy 10.1 GHRH SST
20 wells-jankovic syndrome 10.1 SST VIP
21 adrenal cortical adenocarcinoma 10.1 GHRH SST
22 urethra clear cell adenocarcinoma 10.1 GHRH SST
23 choline deficiency disease 10.1 SST VIP
24 urinary tract papillary transitional cell benign neoplasm 10.1 CHGA GHRH
25 anisometropia 10.1 CHGA SST
26 retinal vascular occlusion 10.1 SCT SST
27 inflammatory diarrhea 10.1 SST VIP
28 chondroma 10.1 SCT SST
29 drug psychosis 10.1 SST VIP
30 vestibular gland benign neoplasm 10.1 CHGA SST
31 parathyroid carcinoma 10.1 CHGA SCT
32 neutropenia, severe congenital, 5, autosomal recessive 10.1 CHGA SST
33 adamantinous craniopharyngioma 10.1 GHRH SST
34 lipid-rich carcinoma 10.1 CHGA VIP
35 bile acid synthesis defect, congenital, 4 10.1 SST VIP
36 insulinoma 10.1
37 adult brain stem glioma 10.1 SCT VIP
38 sweat gland cancer 10.1 SST VIP
39 thrombophilia 10.1 GHRH SST
40 lacrimal system cancer 10.0 SCT SST
41 multiple endocrine neoplasia 10.0
42 chemical colitis 10.0 CHGA CHGB
43 progressive relapsing multiple sclerosis 10.0 CHGA SCT SST
44 edict syndrome 10.0 GHRH SST
45 thyroid gland disease 10.0 SCT SST
46 cardioauditory syndrome of sanchez cascos 10.0 CHGA GHRH SST
47 eccrine papillary adenocarcinoma 10.0 CHGA SCT SST
48 hepatitis b reinfection following liver transplantation 10.0 CHGA GHRH SST
49 ischemic heart disease 10.0 CHGA SCT SST
50 band keratopathy 10.0 SST VIP

Graphical network of the top 20 diseases related to Glucagonoma:



Diseases related to Glucagonoma

Symptoms & Phenotypes for Glucagonoma

Human phenotypes related to Glucagonoma:

56 32 (show all 42)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 56 32 Frequent (79-30%) HP:0000989
2 constipation 56 32 Frequent (79-30%) HP:0002019
3 diarrhea 56 32 Frequent (79-30%) HP:0002014
4 nausea and vomiting 56 32 Frequent (79-30%) HP:0002017
5 depression 56 32 Occasional (29-5%) HP:0000716
6 diabetes mellitus 56 32 Frequent (79-30%) HP:0000819
7 hepatomegaly 56 32 Frequent (79-30%) HP:0002240
8 ascites 56 32 Occasional (29-5%) HP:0001541
9 thromboembolism 56 32 Occasional (29-5%) HP:0001907
10 abnormal blistering of the skin 56 32 Frequent (79-30%) HP:0008066
11 weight loss 56 32 Frequent (79-30%) HP:0001824
12 increased circulating gonadotropin level 56 32 Very rare (<4-1%) HP:0000837
13 anorexia 56 32 Frequent (79-30%) HP:0002039
14 intestinal obstruction 56 32 Occasional (29-5%) HP:0005214
15 chronic fatigue 56 32 Frequent (79-30%) HP:0012432
16 gastrointestinal hemorrhage 56 32 Occasional (29-5%) HP:0002239
17 extrahepatic cholestasis 56 32 Occasional (29-5%) HP:0012334
18 parathyroid adenoma 56 32 Very rare (<4-1%) HP:0002897
19 hypercalcemia 56 32 Very rare (<4-1%) HP:0003072
20 growth hormone excess 56 32 Very rare (<4-1%) HP:0000845
21 subcutaneous lipoma 56 32 Very rare (<4-1%) HP:0001031
22 episodic abdominal pain 56 32 Frequent (79-30%) HP:0002574
23 pituitary adenoma 56 32 Very rare (<4-1%) HP:0002893
24 adrenocortical adenoma 56 32 Very rare (<4-1%) HP:0008256
25 skin rash 56 32 Frequent (79-30%) HP:0000988
26 neoplasm of the pancreas 56 32 Very frequent (99-80%) HP:0002894
27 abnormality of the thyroid gland 56 32 Very rare (<4-1%) HP:0000820
28 glossitis 56 32 Frequent (79-30%) HP:0000206
29 intrahepatic cholestasis 56 32 Occasional (29-5%) HP:0001406
30 prolactin excess 56 32 Very rare (<4-1%) HP:0000870
31 steatorrhea 56 32 Occasional (29-5%) HP:0002570
32 acanthocytosis 56 32 Frequent (79-30%) HP:0001927
33 poor appetite 56 32 Frequent (79-30%) HP:0004396
34 primary hyperparathyroidism 56 32 Very rare (<4-1%) HP:0008200
35 stomatitis 56 32 Frequent (79-30%) HP:0010280
36 intermittent jaundice 56 32 Occasional (29-5%) HP:0001046
37 lack of bowel sounds 56 32 Occasional (29-5%) HP:0030145
38 normochromic anemia 56 32 Frequent (79-30%) HP:0001895
39 abnormal gastrointestinal motility 56 32 Occasional (29-5%) HP:0030895
40 hypercortisolism 56 Very rare (<4-1%)
41 increased circulating cortisol level 32 HP:0003118
42 abnormality of the abdomen 56 Occasional (29-5%)

UMLS symptoms related to Glucagonoma:


diarrhea

Drugs & Therapeutics for Glucagonoma

Drugs for Glucagonoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
6
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
13 Antimetabolites Phase 2, Phase 3,Phase 1
14 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
15 Analgesics Phase 3
16 Adjuvants, Anesthesia Phase 3
17 Narcotics Phase 3
18 Analgesics, Opioid Phase 3
19 Anesthetics Phase 3
20 Anesthetics, General Phase 3
21 Anesthetics, Intravenous Phase 3
22 Peripheral Nervous System Agents Phase 3
23 Central Nervous System Depressants Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
28
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
29
Melphalan Approved Phase 2 148-82-3 4053 460612
30
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
33
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
34
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
35
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
36
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
37
Streptozocin Approved Phase 2 18883-66-4 29327
38
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
39
Pancrelipase Approved Phase 2,Phase 1 53608-75-6
40
Somatostatin Approved Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
41
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
42
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
43
Gemcitabine Approved Phase 2 95058-81-4 60750
44
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
45
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
46
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
47
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
48
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
49
Vatalanib Investigational Phase 2,Phase 1 212141-54-3 151194
50 Topoisomerase Inhibitors Phase 2

Interventional clinical trials:

(show all 34)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
4 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2
5 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2
6 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2
7 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2
8 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2
9 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2
10 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2
11 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2
12 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2
13 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2
14 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
15 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2
16 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2
17 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2
18 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2
19 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2
20 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2
21 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2
22 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2
23 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2
24 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
25 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1
26 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
27 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1
28 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
29 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
30 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1
31 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
32 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
33 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Unknown status NCT00730483
34 Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Enrolling by invitation NCT02102893

Search NIH Clinical Center for Glucagonoma

Genetic Tests for Glucagonoma

Genetic tests related to Glucagonoma:

id Genetic test Affiliating Genes
1 Glucagonoma 29

Anatomical Context for Glucagonoma

MalaCards organs/tissues related to Glucagonoma:

39
Pancreas, Skin, Liver, Pituitary, Thyroid, Heart, Lymph Node

Publications for Glucagonoma

Articles related to Glucagonoma:

(show top 50) (show all 303)
id Title Authors Year
1
Glucagonoma-Associated Rash. ( 28273025 )
2017
2
Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas. ( 28188614 )
2017
3
Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine. ( 28508546 )
2017
4
Necrolytic migratory erythema: A diagnostic clue in glucagonoma syndrome. ( 27567335 )
2017
5
Glucagonoma and Glucagonoma Syndrome: A Case Report with Review of Recent Advances in Management. ( 26981306 )
2016
6
Glucagonoma syndrome: a review and update on treatment. ( 27422767 )
2016
7
Glucagonoma syndrome: report of one case. ( 28138636 )
2016
8
Necrolytic migratory erythema and pancreatic glucagonoma. ( 27622478 )
2016
9
Paediatric necrolytic migratory erythema as a presenting sign of glucagonoma syndrome. ( 26585841 )
2016
10
Glucagonoma syndrome: A case report. ( 26622635 )
2015
11
Proposed Radiation Induced Hormone Crisis in a Patient with Glucagonoma. ( 26493062 )
2015
12
Glucagonoma syndrome associated with necrolytic migratory erythema. ( 26248239 )
2015
13
A Novel Missense Mutation of the MEN1 Gene in a Patient with Multiple Endocrine Neoplasia Type 1 with Glucagonoma and Obesity. ( 26424307 )
2015
14
Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy. ( 26204206 )
2015
15
Reversal of dilated cardiomyopathy after glucagonoma excision. ( 25553769 )
2015
16
Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome. ( 25914784 )
2015
17
Imaging features of glucagonoma syndrome: A case report and review of the literature. ( 25789004 )
2015
18
Delayed diagnosis of glucagonoma syndrome: a case report. ( 26679842 )
2015
19
Paradoxical presentation of glucagonoma with delayed onset of necrolytic migratory erythema. ( 25448171 )
2015
20
Novel mutation 928G>C of MEN1 gene in a familial multiple endocrine neoplasia type 1 case (MEN1) with co-existence of insulinoma and glucagonoma. ( 25047095 )
2014
21
Non-secreting benign glucagonoma diagnosed incidentally in a patient with refractory thrombocytopenic thrombotic purpura: report of a case. ( 25373364 )
2014
22
Glucagonoma syndrome: a case report with focus on skin disorders. ( 25152626 )
2014
23
Glucagonoma-induced acute heart failure. ( 25520848 )
2014
24
Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. ( 26183746 )
2014
25
Pancreatic glucagonoma metastasising to the right ovary five years after initial surgery: a case report. ( 24018597 )
2013
26
Necrolytic migratory erythema and glucagonoma rising from pancreatic head. ( 23890147 )
2013
27
Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections. ( 23389434 )
2013
28
Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: implications for glucagon-like peptide-1 secretion from pancreatic I+ cells in vivo. ( 24008099 )
2013
29
Pancreatic glucagonoma with pancreatic calcification. ( 23719610 )
2013
30
Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. ( 23681843 )
2013
31
An unusual case of subclinical diffuse glucagonoma coexisting with two nodules in the pancreas: characteristic features on computed tomography. ( 22239827 )
2012
32
Necrolytic migratory erythema associated with glucagonoma syndrome diagnosed by (68) Ga-DOTANOC PET-CT. ( 23279825 )
2012
33
Necrolytic migratory erythema as the first manifestation of glucagonoma. ( 22970401 )
2012
34
Bone lesions in recurrent glucagonoma: A case report and review of literature. ( 22737277 )
2012
35
Hypercalcemia appeared in a patient with glucagonoma treated with octreotide acetate long-acting release. ( 23062642 )
2012
36
Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? ( 23259638 )
2012
37
Is necrolytic migratory erythema due to glucagonoma a misnomer? A more apt name might be mucosal and intertriginous erosive dermatitis. ( 22513058 )
2012
38
Diabetes Cured by Pancreaticoduodenectomy: A Case Report of Glucagonoma Masquerading as Carcinoma of the Head of Pancreas. ( 22086709 )
2011
39
A case of a giant glucagonoma with parathyroid hormone-related peptide secretion showing an inconsistent postsurgical endocrine status. ( 21841327 )
2011
40
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia. ( 21824258 )
2011
41
Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. ( 21470282 )
2011
42
Glucagonoma syndrome: a case report. ( 21859461 )
2011
43
Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome. ( 21763589 )
2011
44
Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide. ( 20500495 )
2010
45
Necrolytic migratory erythema associated with glucagonoma syndrome. ( 20530273 )
2010
46
A case of pancreatic glucagonoma with erythema. ( 20530930 )
2010
47
Glucagonoma syndrome and necrolytic migratory erythema. ( 20465606 )
2010
48
Necrolytic migratory erythema due to glucagonoma. ( 20060072 )
2010
49
[Glucagonoma without glucagonoma syndrome]. ( 20499510 )
2010
50
Multimodality treatment of unresectable hepatic metastases from pancreatic glucagonoma. ( 21139900 )
2009

Variations for Glucagonoma

Expression for Glucagonoma

Search GEO for disease gene expression data for Glucagonoma.

Pathways for Glucagonoma

Pathways related to Glucagonoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.3 GHRH SCT VIP
2 9.47 SCT VIP

GO Terms for Glucagonoma

Cellular components related to Glucagonoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 CHGA GHRH SCT SST
2 extracellular region GO:0005576 9.1 CHGA CHGB GHRH SCT SST VIP
3 secretory granule GO:0030141 8.96 CHGA CHGB

Biological processes related to Glucagonoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cAMP biosynthetic process GO:0030819 8.62 GHRH SCT

Molecular functions related to Glucagonoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 CHGB SCT SST VIP

Sources for Glucagonoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....